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Lactate dehydrogenase (LDH) in serum has recently been introduced into the American Joint Committee on Cancer (AJCC) staging
system for cutaneous melanoma because of its prognostic value. We hypothesised LDH to be of value in discriminating melanoma
patients entering AJCC stage IV from patients staying in AJCC stages I, II or III. Lactate dehydrogenase was compared to the acute
phase protein C-reactive protein (CRP), which we observed to reflect the course of melanoma metastasis in a previous report. In this
prospective study, we measured LDH and CRP in the serum of 91 consecutive melanoma patients progressing into AJCC stage IV in
comparison to 125 patients staying in AJCC stages I, II or III. Comparing distributions of the parameters by median values and quartiles
by Mann–Whitney test, LDH was not significantly elevated in patients entering AJCC stage IV melanoma (P¼0.785), whereas CRP
was (Po0.001). Analysing the sensitivity and the specificity jointly by the areas under the receiver operating characteristics curves
(ROC-AUC), LDH did not discriminate between the defined groups of patients (AUC¼0.491; 95% confidence interval, 0.410,
0.581), whereas CRP did (AUC¼0.933; 95% confidence interval, 0.900, 0.966; Po0.001). Upon logistic regression analysis to
calculate the ROC-AUC values upon the predictive probabilities, LDH provided no additional information to CRP. Choosing a cutoff
point of 3.0mgl
 1, CRP yielded a sensitivity of 0.769 together with a specificity of 0.904 in diagnosing AJCC stage IV entry.
Altogether, for first diagnosing AJCC stage IV melanoma, CRP is the superior serum marker when compared to the conventional
LDH.
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Melanomas are one of the most aggressive of the skin cancers
and have shown a dramatic increase in incidence over the past
decades (Rigel et al, 1996). Following excision of the primary
tumour, patients are followed up in regular intervals in order to
detect distant metastases early and thus to, if possible, get
patients free of disease by surgery or to monitor the course of
metastasis during chemotherapy. In these follow-up examina-
tions, serum parameters, such as S100b or melanoma-inhibiting
activity (MIA), have been evaluated for discriminating progres-
sive from nonprogressive American Joint Committee on Cancer
(AJCC) stage IV disease; unfortunately, these markers did not
provide additional significant information to the conventional
lactate dehydrogenase (LDH; Deichmann et al, 1999), which is
the most predictive independent factor of diminished survival
upon multivariate analysis, even after accounting for site and
number of metastases (Sirott et al, 1993; Eton et al, 1998; Franzke
et al, 1998; Keilholz et al, 1998). Lactate dehydrogenase has not
only prognostic value in melanoma but also in further tumours,
for example, small-cell and non-small-cell lung cancer, Hodgkin’s
and Non-Hodgkin’s lymphoma or prostate cancer (Sirott et al,
1993). In view of the favourite data in melanoma, LDH has even
been introduced into the new classification system of the AJCC
(Balch et al, 2001).
Unexpectedly, prospective studies with statistically assessable
cohorts of patients have not yet been conducted to evaluate the
value of LDH in discriminating melanoma patients entering AJCC
stage IV from patients staying in AJCC stages I, II or III during
follow up. We therefore initiated the present study and measured
LDH in a consecutive series of 91 patients with first diagnosis of
AJCC stage IV melanoma in comparison to 125 patients staying in
AJCC stages I, II or III. In parallel, we also measured the acute
phase protein C-reactive protein (CRP), which we previously
found to reflect the course of distant metastasis (Deichmann et al,
2000; Deichmann et al, 2001). Distributions of the parameters by
median values and quartiles were compared by Fisher’s exact test
and the Mann–Whitney test. The sensitivity and the specificity
were jointly analysed by the areas under the receiver operating
characteristics curves (ROC-AUC).
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lPATIENTS AND LABORATORY ANALYSES
Between April 1999 and April 2004, 91 consecutive patients with
metastatic melanoma were entered onto the study. All patients had
histologically confirmed melanoma (20 superficial spreading, 12
nodular, five acral lentiginous, 24 cutaneous melanomas not
further classified, nine uveal, nine mucosal, 12 no primary
tumour). The time point of entry into the study was the first
diagnosis of clinical stage IV according to the AJCC criteria (Balch
et al, 2001). Metastases were diagnosed by clinical examination,
chest X-rays, ultrasound, computed axial tomography scans and
nuclear magnetic resonance imaging. A total of 11 patients
suffered from distant skin, subcutaneous or lymph node metas-
tases, 19 patients had lung metastases, and other visceral
metastases were found in 61 patients.
Blood samples were taken at the time of the first diagnosis of
AJCC stage IV melanoma. Lactate dehydrogenase was tested on a
Beckman LX20 instrument (Beckman Instruments, Gagny,
France), and CRP was assayed by a rate immunonephelometric
technique on a protein system analyser (BN2 Array; Dode-Behring,
Munich, Germany).
In total, 125 consecutive melanoma patients, not being
diagnosed as AJCC stage IV in follow-up examinations, entered
onto the study as cohort for comparison. Again, these patients had
histologically confirmed melanoma (53 superficial spreading, 26
nodular, 10 acral lentiginous, four lentiginous, 31 cutaneous
melanomas not further classified, one no primary tumour). At the
time point when blood was drawn, these patients were diagnosed
as melanoma stage I (21 patients), stage II (49 patients) and stage
III (55 patients) according the AJCC criteria (Balch et al, 2001).
Statistical analyses
All statistics and figures were computed with the statistical
software SPSS (SPSS Inc., Release 10.0.7, Chicago, IL, USA). We
report two-tailed statistics throughout, a P-value smaller than 0.05
(Po0.05) was considered significant. Two-sample comparisons
were performed by Fisher’s exact test (sex) and the Mann–
Whitney test (age, LDH, CRP). The receiver operating character-
istics (ROC) analysis was used to evaluate the ability of the
conventional serum marker LDH and the CRP serum values to
discriminate between patients entering AJCC stage IV (IVþ) from
those staying in AJCC stages I, II or III (IV ). The primary result
of the ROC analysis was the area under the curve (AUC), which is a
measure for the effect size. The AUC corresponds to the
probability that a randomly chosen pair from (IVþ,I V  )i s
diagnosed correctly. An AUC of 0.5 or below indicates that a
diagnostic tool does not discriminate better than chance between
IVþ and IV  patients, an AUC of 1 indicates a perfect
discriminability. The ROC analysis can be conducted choosing
the values of the markers themselves as cutoff points or,
alternatively, the predictive probabilities that result from a logistic
regression with the markers as independent variables. To compare
the discriminability of the marker CRP alone to the discrimin-
ability of the marker CRP in combination with the conventionally
used marker LDH, we conducted two logistic regressions: one
on CRP alone and one on CRP in combination with LDH. The
null hypothesis H0 : AUCCRP   AUCCRPþLDH ¼ 0 against HA :
AUCCRP   AUCCRPþLDH 6¼ 0 was then tested using the test statistic
derived for correlated AUCs by Hanley and McNeil (1983). For the
diagnostic procedure proven to be superior, sensitivities and cutoff
points are given for the specificities of 0.8, 0.85 and 0.9.
RESULTS
Comparing the melanoma patients entering AJCC stage IV with
those staying in AJCC stages I, II and III, both groups did not differ
significantly in sex and age (Table 1). Describing their distribu-
tions by median values and quartiles using the Mann–Whitney
test, serum CRP was markedly elevated in patients entering AJCC
stage IV melanoma (Po0.001), whereas LDH was not (P¼0.785;
Table 1).
Estimates for both sensitivity and specificity in separating
patients entering AJCC stage IV melanoma from those staying in
AJCC stages I, II or III were obtained using ROC analysis. The
figure already indicates that the ability of discrimination of the
marker CRP is clearly better than one of the marker LDH
(Figure 1). The AUC analysis confirms that LDH (AUC¼0.491;
Table 1 Median, lower and upper quartiles, and P-values according to two-sample comparisons
Melanoma AJCC stage IV Melanoma not AJCC stage IV
Median Lower and upper quartiles Median Lower and upper quartiles P
a
No. of patients 91 125
Male (%) 59.3 55.2 0.580
Age (years) 59 51–69 58 46–69 0.397
LDH (Ul
 1) 197 150–328 208 185.5–235.5 0.785
CRP (mgl
 1) 14.8 3.6–44.2 o2 o2–o2
b o0.001
aFisher’s exact test (sex) and Mann–Whitney test.
bMaximum: 7.7, 95% quantile: 5.47. LDH¼lactate dehydrogenase; CRP¼C-reactive protein.
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Figure 1 Receiver operating characteristic (ROC) curves for the serum
parameters LDH (grey line) and CRP (black line). As the area under the
curve (AUC) is larger for CRP, this marker is better in discriminating
melanoma patients entering AJCC stage IV from patients staying in stages I,
II or III in follow-up examinations.
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l95% confidence interval (0.410, 0.581)) did not discriminate
significantly (P¼0.823), whereas CRP did for the considered
population (AUC¼0.933; 95% confidence interval (0.900, 0.966);
Po0.001).
Next, we compared CRP to the combination of CRP and LDH in
the diagnosis of AJCC stage IV melanoma entry. We conducted
logistic regressions on CRP alone and on CRP and LDH together.
Denoting by p the probability that a patient has entered AJCC
stage IV, the logistic regression on CRP yielded p¼1/
(1þexp( ( 2.906þ0.575 Xcrp)), where Xcrp denoted the amount
of CRP measured. The logistic regression on CRP and LDH yielded
p¼1/(1þexp( ( 1.7147þ0.626Xcrp 0.006Xldh)), where Xcrp and
Xldh denoted the amount of CRP and LDH measured, respectively.
Using the predicted probabilities for a patient being diagnosed to
enter AJCC stage IV as cutoff points, the ROC curve of CRP alone
diagnosing entry AJCC stage IV was then compared with the ROC
curve of CRP and LDH together (Figure 2). The figure already
indicates that CRP alone is slightly better than the combination of
CRP and LDH. We compared the corresponding AUCs of CRP
alone which resulted to be 0.933 (standard deviation (s.d.), 0.017;
95% confidence interval, 0.900, 0.966) and CRP combined with
LDH which was 0.913 (0.022; 95% confidence interval, 0.869, 0.957).
To test whether the AUC of CRP in combination with LDH is
significantly larger than the AUC of CRP alone, we applied the
Hanley–McNeil test statistic, calculating the correlation using
Kendall’s t of the predictive probabilities of CRP and CRP in
combination with LDH for patients with and without AJCC stage
IV diagnosis, respectively. This lead to correlations of 0.475 for
patients with distant metastases and 0.917 for patients without
distant metastases. Pooling these values gave an average
correlation of 0.696. Together with the mean AUCs of 0.923, we
derived the correlation coefficient r between the two AUC from
the tables given by Hanley and McNeil (1983), which was 0.60.
The Hanley–McNeil test statistic z ¼ð AUCCRP   AUCCRPþLDHÞ= ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
sðAUCCRPÞ
2þsðAUCCRPþLDHÞ
2 2rsðAUCCRPÞsðAUCCRPþLDHÞ
q
with
AUCCRP and AUCCRPþLDH being the areas under the curve for
CRP and the combination of CRP and LDH and s(AUCCRP) and
s(AUCCRPþLDH) their s.d.’s yielded a value of 1.11, which can be
compared to the critical values of the normal distribution. Hence,
the null hypothesis could not be rejected: the AUC of CRP in
combination with LDH could not be proven to be significantly
larger than the AUC of CRP alone.
The marker CRP thus was proven to discriminate better than
LDH between patients entering AJCC stage IV from patients
staying in AJCC stages I, II or III. To reach a specificity of about
0.8, one could either choose a cutoff point of 2.1 leading to a
specificity of 0.792 or a cutoff point of 2.2 leading to a specificity of
0.816. Both cutoff points corresponded to sensitivities of 0.835. For
a specificity of about 0.85, the cutoff points of 2.4 or 2.5 yielded
specificities of 0.832 and 0.856, respectively. Both cutoff points
corresponded to sensitivities of 0.813. With a cutoff point of 2.9, a
specificity of 0.896 was reached together with a sensitivity of 0.791,
while a cutoff point of 3.0 yielded a specificity of 0.904 together
with a sensitivity of 0.769.
DISCUSSION
For discriminating melanoma patients entering AJCC stage IV
from patients staying in AJCC stages I, II or III during follow up,
LDH is not suitable, regardless of its proven prognostic value in
AJCC stage IV (Sirott et al, 1993; Eton et al, 1998; Franzke et al,
1998; Keilholz et al, 1998; Balch et al, 2001). Unexpectedly, CRP
resulted as the more favourite serum marker: This acute phase
protein was superior to LDH and contributed significantly in
discriminating melanoma patients entering AJCC stage IV from
patients staying in AJCC stages I, II or III.
C-reactive protein was introduced in this study as elevated levels
in serum have been associated with shortened survival in
metastatic melanoma patients and resistance to interleukin-2
therapy (Tartour et al, 1994; Mouawad et al, 1996; Tartour et al,
1996). In line with this report, we previously observed high CRP
levels to indicate progression of distant metastases during therapy
(Deichmann et al, 2000). As a nonspecific acute phase response to
almost all forms of inflammation (Pepys, 1995), CRP is synthesised
in hepatocytes in response to cytokines such as mainly interleukin-
6 (Il-6; Moshage et al, 1988; Castell et al, 1989; Kishimoto, 1989;
Klein et al, 1991; Hirano, 1992). As melanoma cells are known to
produce Il-6 (Colombo et al, 1992; Lee et al, 1992; Lu and Kerbel
1993; Mattei et al, 1994; Francis et al, 1996), serum CRP might
reflect Il-6 production from the tumour. However, tumour-specific
immune interaction with T cells, macrophages or monocytes might
also be responsible for elevated Il-6 levels, as these cell are known
to produce this cytokine, too. Further major sources of Il-6 may be
surrounding fibroblasts or endothelial cells (Kishimoto, 1989). In
vivo, CRP reflects Il-6 secretion (Klein et al, 1991) supported by
high correlation between serum CRP and Il-6 concentrations in
melanoma patients (Moshage et al, 1988; Castell et al, 1989;
Kishimoto, 1989; Klein et al, 1991; Hirano, 1992; Tartour et al,
1996; Deichmann et al, 2000).
As Il-6 is known to inhibit the activity of lipoprotein lipase, a key
regulatory enzyme for triglyceride clearance from plasma, in-
creased levels of its surrogate CRP were positively correlated with
the paraneoplastic inflammatory syndrome, leading to weight loss
cachexia (Mahmoud and Rivera, 2002). Besides melanoma (Tartour
et al, 1994; Tartour et al, 1996), high CRP serum levels are known to
indicate shorter median survival in patients suffering from other
tumours such as renal cell carcinoma (Blay et al, 1992) or colorectal
carcinoma (Gough et al, 1996; Nozoe et al, 1998; Mahmoud and
Rivera, 2002). Thus, CRP is not exclusively increased in melanoma.
This protein is produced as a nonspecific acute phase response to
almost all forms of inflammation (Pepys, 1995).
Altogether, LDH did not discriminate melanoma patients
entering AJCC stage IV from patients staying in AJCC stages I, II
or III in follow-up examinations, whereas CRP did upon ROC-AUC
analysis. Choosing a cutoff point of 3.0mgl
 1, CRP yielded a
ROC curve
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Figure 2 Receiver operating characteristic (ROC) curves for the
parameter CRP (black line) in comparison to the combination of CRP
and LDH (grey line) in discriminating melanoma patients entering AJCC
stage IV from patients staying in stages I, II or III in follow-up examinations.
The area under the curve (AUC) of CRP alone (0.933) is larger than the
AUC of CRP in combination with LDH (0.913); still this difference was not
statistically significant.
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lsensitivity of 77% together with a specificity of 90% in diagnosing
AJCC stage IV entry. Following excision of the primary melanoma,
CRP measurement may contribute to earlier detection of distant
metastasis, possibly getting some patients free of disease by
surgery or radiation. We therefore recommend the routine
measurement of CRP in follow-up examinations of melanoma
patients, which is a simple and cheap test and provides valuable
information.
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